CloudMD Software & Services Inc., - CEO, Dr Essam Hamza.
CEO, Dr Essam Hamza.
Source: The Vancouver Sun.
  • CloudMD (DOC) has closed its acquisition of VisionPros, a rapidly growing digital eyewear platform
  • VisionPros’ 2020 revenue surpassed C$22 million with an adjusted EBITDA margin exceeding 10 per cent
  • The company is vertically integrated and has serviced almost 1 million unique customers across North America
  • CloudMD believes that VisionPros’ digital platform affords significant opportunities for cross-selling and integration
  • CloudMD is building a connected platform that addresses all points of a patient’s health care journey
  • CloudMD Software and Services (DOC) is trading flat at $1.88 per share

CloudMD (DOC) has closed its acquisition of VisionPros, a rapidly growing digital eyewear platform.

Highlights

  • VisionPros is vertically integrated and has serviced almost 1 million unique customers across North America
  • The company’s 2020 revenue surpassed C$22 million with an adjusted EBITDA margin exceeding 10 per cent
  • The company delivers contact lenses and glasses at a fraction of the cost of traditional retail optical stores
  • The scalable business model includes an e-commerce platform and an innovative suite of digital vision care tools
  • The company also offers a competitive subscription option, a brick-and-mortar clinic and its own affordable eyewear line

CloudMD believes that VisionPros’ digital platform affords significant opportunities for cross-selling and integration.

Terms of acquisition

CloudMD acquired VisionPros for $30 million in cash and $30 million in CloudMD common shares priced at $2.75 per share. The company may also pay a performance-based earnout up to $40 million.

In addition, CloudMD may pay up to $20 million upon the development of certain new technologies prior to December 31, 2022.

CloudMD is building a connected platform that addresses all points of a patient’s health care journey.

CloudMD Software and Services (DOC) is trading flat at $1.88 per share as of 9:31 am ET.

More From The Market Online

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.

WELL Health and Microsoft to future-proof North American healthcare

WELL Health Technologies (TSX:WELL) and Microsoft (NDAQ:MSFT) sign a five-year deal to expedite healthcare's transition into the digital age.